Avelas Biosciences to Present at Piper Jaffray Healthcare Conference

SAN DIEGO, November 21, 2017 – Avelas Biosciences, Inc., a clinical stage oncology-focused company dedicated to improving cancer patient care from diagnosis through treatment, today announced that Carmine N. Stengone, president and chief executive officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017, at 4:50 p.m. EST (1:50 p.m. PST) in New York City.

About Avelas Biosciences

Avelas Biosciences is a San Diego-based biotechnology company focused on developing technologies that advance a new standard-of-care for cancer surgery and therapeutic intervention. The company’s lead candidate, AVB-620, has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. A Phase 2 clinical trial for AVB-620 in breast cancer is ongoing. In addition, the company is advancing a therapeutic program, which utilizes the same technology platform. Avelas was founded by Avalon Ventures on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry.

« Return